Clinical Quiz: Long-term Gout Management and Special Considerations from 2020 ACR Gout Guidelines

News
Article

This clinical quiz, our last in a series of 4, focuses on recommendations for special populations and long-term management from the 2020 ACR gout guidelines.

HCPLive clinical quiz image. Credit: HCPLive

Gout is a growing public health burden that impacts approximately 4% of US adults, with a prevalence that has more than doubled from the 1960s and is expected to continue to rise in the coming decades.1,2

Gout requires careful management to maintain quality of life and there are many factors for rheumatologists to take into account when treating patients with gout and particular considerations for people with comorbidities, as gout is a chronic disease that must be monitored and managed long-term.

In 2020, the American College of Rheumatology (ACR) issued new guidance and recommendations for the management of gout. The 17-page document, which was the group's first new guideline on the topic since 2012, contained 42 recommendations, including 16 strong recommendations. In this clinical quiz, the third in a series of 4 based on the guideline, we test your knowledge on the management of gout flares.3

True or False: In patients with chronic kidney disease, febuxostat is preferred over allopurinol for ULT.


Check out other quizzes on the 2020 ACR gout guidelines:

Initiation and titration of urate-lowering therapy

Gout flare management

Clinical Quiz: Lifestyle and Comorbidities from 2020 ACR Gout Guidelines

References:

  1. National Kidney Foundation. Quick facts: Gout and chronic kidney disease. National Kidney Foundation. August 19, 2024. Accessed August 25, 2024. https://www.kidney.org/kidney-topics/quick-facts-gout-and-chronic-kidney-disease.
  2. GBD 2021 Gout Collaborators. Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2024;6(8):e507-e517. doi:10.1016/S2665-9913(24)00117-6
  3. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout [published correction appears in Arthritis Care Res (Hoboken). 2020 Aug;72(8):1187. doi: 10.1002/acr.24401] [published correction appears in Arthritis Care Res (Hoboken). 2021 Mar;73(3):458. doi: 10.1002/acr.24566]. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi:10.1002/acr.24180
Recent Videos
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Jessica Crimaldi, NP | Credit: Jessica Crimaldi on LinkedIn
Harpreet Bhatia, MD: Benefits of Universal Screening for Lp(a) Levels
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Responding to FDA Approval of Lebrikizumab for Atopic Dermatitis, with Andrew Alexis, MD, MPH
© 2024 MJH Life Sciences

All rights reserved.